Chicago-based biotech Cour Pharmaceuticals announced the hiring of former Acelyrin executive Paul M. Peloso, MD as chief ...
As I spent time at home recuperating after the procedure, the emotional turmoil continued. I wept. I searched. I prayed. I ...
“I think it's going to get worse.” As an example from history that could repeat, Egan cites Arcoxia (etoricoxib), the second-generation COX-2 inhibitor from Merck. At an FDA advisory panel ...
Dr. Peloso to lead COUR’s clinical development programs as the company advances towards late-stage developmentCHICAGO, May 21, 2024 (GLOBE NEWSWIRE) -- COUR Pharmaceuticals, a clinical-stage ...
The combined assessment of analysts suggests that 'Revenue- Established Brands- Int'l- Non-Opioid Pain, Bone and Dermatology- Arcoxia' will likely reach $67.07 million. The estimate indicates a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback